Teva closing in on $40B buy of Allergan generics unit
Teva’s acquisition will make it the world’s largest maker of generic medicines, giving it greater negotiating power with governments and private-health insurers.
Pharmaceutical
Articles
Lawmakers zeroing in on anti-meth plan
Bills would let pharmacists require prescriptions for suspicious customers trying to buy cold medicines with pseudoephedrine. But some drug store chains fear putting their pharmacists in danger.
Kroger to offer anti-overdose drug without prescription
The supermarket chain will make naloxone available in its pharmacies across Ohio and northern Kentucky, a region hard-hit by deadly heroin.
Proposal for cold medicine prescriptions being scaled back
The new version of the Indiana bill would classify pseudoephedrine in a way that most consumers would be able to buy it, but pharmacists could require a prescription from suspicious customers.
UPDATE: Pharmacist consultation bill clears senate committee
Indiana pharmacists could get the legal right to refuse to sell a common cold medicine used to make methamphetamine to suspicious customers under a bill a Senate committee approved Tuesday.
Lilly’s 2016 sales, profit guidance falls short of predictions
Indianapolis-based Eli Lilly and Co., which has promised to return to growth after a half-decade of falling revenue, indicated that 2016 earnings might be below analysts’ estimates.
First-of-a-kind drug approvals continued rise in 2015
The rising figures reflect an industry-wide focus on drugs for rare and hard-to-treat diseases, which often come with streamlined reviews, extra patent protections and higher price tags.
Deal puts IU doctor’s research on path to market
A professor in the Indiana School of Medicine is hopeful that an antibiotic cocktail he invented will one day improve the lives of millions of people, thanks in part to the Indiana University Research and Technology Corp., formed in 1997 to make work done by IU faculty and researchers available for commercial development.
Lilly could pay $800M-plus in pact with drug-tech firm
The companies will work on coupling therapies from Lilly with technology from Halozyme Therapeutics that helps the body disperse and spread medicine.
FDA OKs once-a-day insulin that could be blockbuster for Lilly
The FDA said Wednesday it approved Basaglar based on data showing it is safe and effective and works similarly to Lantus, the world’s top-selling insulin.
Autism likelier when antidepressants taken during pregnancy
A new study says women who took a common class of antidepressants during the second and third trimesters were more than twice as likely than other women to have children who later developed autism.
Eli Lilly ends development of promising insulin drug
Eli Lilly said Friday that it decided to stop developing the insulin peglispro after learning that it would take more time and cost more than expected to understand a significant side effect.
Experts see big premium increases for Medicare drug plan
With time running out on open-enrollment season, many seniors are facing sharply higher costs for Medicare's popular prescription drug program after a long stretch of stable premiums.
Pfizer-Allergan $160B deal forms world’s largest drugmaker
It's also the largest so-called inversion, where an American corporation combines with a company headquartered in a country with a lower corporate tax rate, saving potentially millions each year in U.S. taxes.
U.S. doctors group calls for drug advertising ban
In a vote Tuesday, the American Medical Association called for an end to television commercials and magazine spreads that are used to pitch prescription drugs directly to consumers.
Bosma backs proposal to require pseudoephedrine prescription
Bosma’s support could give the proposal its first real life in the General Assembly, which has for years eschewed prescription proposals in favor of laws that require pharmacies to track the people who purchase drugs containing pseudoephedrine, one of the ingredients that can be used to make meth.
Despite wealth of attention, new female libido pill isn’t selling
The number of prescriptions for Addyi, the women’s libido-boosting pill, in its first few weeks? 227.
Lilly, other drugmakers face federal pricing probe
Indianapolis-based Eli Lilly and Co. and other U.S. drugmakers are being investigated by federal prosecutors over their drug-pricing practices related to Medicare and Medicaid, according to newspaper reports.
Soaring Rx costs lift firm’s prospects, job creation
Rx Help Centers assists employers and customers as they navigate through the confusing web of prescription drug discounts. Business is so good that the company hopes to add 250 workers by 2017.
Pharmaceutical firms losing business to darknet drug deals
For the $300 billion pharmaceutical industry, the rapid growth of illegal underground marketplaces is a serious threat to profits and reputations.